Project Grant CLSS00000059472

The federal Project Grant award with ID DP2DA062283 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The $2,542,500 grant, awarded on September 1, 2024, will support the development of novel econometric methods and a unified framework for integrating real-world evidence (RWE) to analyze inconclusive randomized controlled trials (RCTs) focused on opioid use disorder (OUD) treatments. The project, to be conducted by Weill...

Federal Grant Award Summary The Naloxone Project (TNP) received a $600,000 Project Grant award effective September 1, 2025, through August 31, 2026, from the Federal Office of Rural Health Policy under the Rural Healthcare Services Programs (CFDA 93.912). The COLORADO CHANGE (Coalition for Harm Reduction, Access to Naloxone, and Grassroots Rural Engagement) project addresses the opioid overdose crisis in Colorado's rural communities, where opioids were involved in over 62% of the state's 7,022...

The Department of Justice, Office of Justice Programs, Bureau of Justice Assistance awarded a $1,600,000 Comprehensive Opioid, Stimulant, and other Substances Use Program (CFDA 16.838) Project Grant to the Southern Nevada Health District (SNHD) and sub-recipients Las Vegas Metropolitan Police Department (LVMPD) and University of Nevada, Las Vegas (UNLV). The grant will fund a collaborative initiative to address the opioid crisis in Clark County, Nevada through a public health-focused overdose...

Federal Grant Award Summary Louisiana State University Health Sciences Center New Orleans received a $225,065 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective August 15, 2025, with a completion date of July 31, 2027. The award supports research on targeting the renin system as a novel therapeutic approach for managing chronic pain and opioid use disorder (OUD). The project leverages the FDA-approved...

Federal Grant Award Summary The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded the University of Pittsburgh a $198,164 Project Grant on September 25, 2025, to support basic neuroscience research investigating delta opioid receptor (DOR) regulation in the prefrontal cortex and its relationship to opioid use disorder (OUD) and oxycodone-related behavioral outcomes. The research will be conducted in Pittsburgh, Pennsylvania,...

This $424,545 Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) will support a national survey on naloxone use and access. The survey, conducted by the RAND Corporation, will provide critical, timely evidence on the state of naloxone carrying and purchasing behavior in the U.S., including the impact of recently approved over-the-counter naloxone products. The project will monitor knowledge, barriers, and willingness-to-pay...

Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded $709,085 to the University of Colorado-Denver for an implementation research trial commencing April 1, 2026, and concluding January 31, 2031. This project delivers implementation facilitation services and clinical intervention support designed to expand in-hospital opioid treatment program (OTP) intakes for hospitalized patients with opioid...

Federal Project Grant Summary Berkshire Biomedical Corporation received a $326,410 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective June 1, 2025 through May 31, 2027. The award funds COPA (A Clinical Program to Evaluate Benefits of a Hand-Held, Automated, Personalized Oral Liquid Dispensing System), a clinical research initiative designed to evaluate a hand-held automated dispensing device for...

Federal Grant Award Summary Altrumed LLC received an $808,156 Project Grant award from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) for the period of August 15, 2025, through July 31, 2026. The grant funds development of DOVE (Device-Agnostic Hypoxia Detection Software), an innovative shoulder-wearable sensor system combined with advanced software designed to predict fatal opioid overdoses and guide real-time intervention by responders....

Federal Grant Award Summary Brigham & Women's Hospital Inc. received a $557,105 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) for the Public Access Naloxone Design, Dissemination and Assessment (PANDDA) project, awarded April 1, 2026, with completion targeted for March 31, 2028. The project delivers a comprehensive, evidence-based framework for deploying public access naloxone (PAN) programs through two phases:...